Decitabine (DAC) Vs. Best Supportive Care in Elderly Patients with Intermediate- and High-Risk MDS with or without Monosomal Karyotypes: Results of the EORTC-LG/German MDS-SG Randomized Phase III Trial 06011.

被引：0
|
作者：
Luebbert, Michael [1 ]
Suciu, Stefan [2 ]
Hagemeijer, Anne [3 ]
Bogatyreva, Ljudmila [1 ]
Rueter, Bjoern [1 ]
Platzbecker, Uwe [4 ]
Giagounidis, Aristoteles [5 ]
Selleslag, Dominik [6 ]
Labar, Boris [7 ]
Germing, Ulrich [8 ]
Salih, Helmut R. [9 ]
Meert, Liv [2 ]
Muus, Petra [10 ]
Pflueger, Karl-Heinz [11 ]
Kuendgen, Andrea [8 ]
Aul, Carlo [5 ]
de Witte, Theo M. [10 ]
Ganser, Arnold [12 ]
Marie, Jean-Pierre [13 ]
Wijermans, Pierre W. [14 ]
机构：
[1] Univ Hosp Freiburg, Dept Hematol & Oncol, Freiburg, Germany
[2] EORTC Headquarters, Brussels, Belgium
[3] Univ Louvain, Ctr Human Genet, Louvain, Belgium
[4] Univ Dresden Carl Gustav Carus, Dept Hematol, Dresden, Germany
[5] St Johannes Hosp, Duisburg, Germany
[6] Acad Hosp St Jan, Dept Hematol, Brugge, Belgium
[7] Univ Hosp Ctr Rebro, Zagreb, Croatia
[8] Univ Hosp Dusseldorf, Dusseldorf, Germany
[9] Univ Tubingen, Dept Hematol & Oncol, Tubingen, Germany
[10] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands
[11] DIAKO Bremen, Bremen, Germany
[12] Hannover Med Sch, Hannover, Germany
[13] Hop St Antoine, APHP, Dept Hematol, F-75571 Paris, France
[14] Haga Ziekenhuis, The Hague, Netherlands
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.2804.2804
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2804
引用
收藏
页数：3
相关论文
共 11 条
  • [1] Decitabine vs. best supportive care in elderly higher-risk MDS patients with or without monosomal karyotypes: EORTC-LG/GMDS-SG phase III trial 06011
    Luebbert, M.
    Suciu, S.
    Hagemeijer, A.
    Platzbecker, U.
    Giagounidis, A.
    Selleslag, D.
    Germing, U.
    Salih, H. R.
    Muus, P.
    Bogatyreva, L.
    Aul, C.
    De Witte, T.
    Ganser, A.
    Huls, G.
    Marie, J. P.
    Wijermans, P.
    LEUKEMIA RESEARCH, 2013, 37 : S147 - S147
  • [2] Prognostic Importance of Duration of MDS Prior to Randomization Between Decitabine (DAC) Vs. Best Supportive Care (BSC) In Elderly IPSS Intermediate-2 and High Risk MDS Patients: Results of the 06011 EORTC-GMDSSG Phase III Trial
    Lubbert, Michael
    Suciu, Stefan
    Platzbecker, Uwe
    Giagounidis, Aristoteles A. N.
    Selleslag, Dominik
    Labar, Boris
    Germing, Ulrich
    Kuendgen, Andrea
    Salih, Helmut R.
    Muus, Petra
    Rueter, Bjoern
    Ganser, Arnold
    Aul, Carlo
    de Witte, Theo
    Wijermans, Pierre W.
    BLOOD, 2010, 116 (21) : 1640 - 1640
  • [3] Low Dose Decitabine Versus Best Supportive Care in Elderly Patients with Intermediate or High Risk MDS Not Eligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study (06011) of the EORTC Leukemia and German MDS Study Groups
    Wijermans, Pierre
    Suciu, Stefan
    Baila, Liliana
    Platzbecker, Uwe
    Giagounidis, Aristoteles
    Selleslag, Dominik
    Labar, Boris
    Salih, Helmut
    Beeldens, Filip
    Muus, Petra
    de Witte, Theo
    Luebbert, Michael
    BLOOD, 2008, 112 (11) : 90 - 90
  • [4] Low-Dose Decitabine Vs Best Supportive Care In Older Patients With AML and Low Blast Counts: Results Of a Subgroup Analysis Of The Randomized Phase III Study 06011 Of The EORTC Leukemia Cooperative Group and German MDS Study Group
    Becker, Heiko
    Suciu, Stefan
    Rueter, Bjorn
    Platzbecker, Uwe
    Giagounidis, Aristoteles
    Selleslag, Dominik
    Labar, Boris
    Germing, Ulrich
    Salih, Helmut R.
    Muus, Petra
    Pfluger, Karl-Heinz
    Hagemeijer, Anne
    Schaefer, Hans-Eckart
    Baron, Frederic
    Ganser, Arnold
    Aul, Carlo
    de Witte, Theo
    Wijermans, Pierre W.
    Luebbert, Michael
    BLOOD, 2013, 122 (21)
  • [5] Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group
    Michael Lübbert
    Stefan Suciu
    Anne Hagemeijer
    Björn Rüter
    Uwe Platzbecker
    Aristoteles Giagounidis
    Dominik Selleslag
    Boris Labar
    Ulrich Germing
    Helmut R. Salih
    Petra Muus
    Karl-Heinz Pflüger
    Hans-Eckart Schaefer
    Lioudmila Bogatyreva
    Carlo Aul
    Theo de Witte
    Arnold Ganser
    Heiko Becker
    Gerwin Huls
    Lieke van der Helm
    Edo Vellenga
    Frédéric Baron
    Jean-Pierre Marie
    Pierre W. Wijermans
    Annals of Hematology, 2016, 95 : 191 - 199
  • [6] Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group
    Luebbert, Michael
    Suciu, Stefan
    Hagemeijer, Anne
    Rueter, Bjoern
    Platzbecker, Uwe
    Giagounidis, Aristoteles
    Selleslag, Dominik
    Labar, Boris
    Germing, Ulrich
    Salih, Helmut R.
    Muus, Petra
    Pflueger, Karl-Heinz
    Schaefer, Hans-Eckart
    Bogatyreva, Lioudmila
    Aul, Carlo
    de Witte, Theo
    Ganser, Arnold
    Becker, Heiko
    Huls, Gerwin
    van der Helm, Lieke
    Vellenga, Edo
    Baron, Frederic
    Marie, Jean-Pierre
    Wijermans, Pierre W.
    ANNALS OF HEMATOLOGY, 2016, 95 (02) : 191 - 199
  • [7] Improving clinical and quality-of-life outcomes: Results of a phase III trial of decitabine (DAC) vs supportive care (SC) in patients with myelodysplastic syndromes (MDS).
    Davis, J
    Saba, H
    De Castro, C
    ONCOLOGY NURSING FORUM, 2006, 33 (02) : 439 - 439
  • [8] Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG)
    Becker, Heiko
    Suciu, Stefan
    Rueter, Bjoern Hans
    Platzbecker, Uwe
    Giagounidis, Aristoteles
    Selleslag, Dominik
    Labar, Boris
    Germing, Ulrich
    Salih, Helmut R.
    Muus, Petra
    Pflueger, Karl-Heinz
    Hagemeijer, Anne
    Schaefer, Hans-Eckart
    Fiaccadori, Valeria
    Baron, Frederic
    Ganser, Arnold
    Aul, Carlo
    de Witte, Theo
    Wijermans, Pierre W.
    Luebert, Michael
    ANNALS OF HEMATOLOGY, 2015, 94 (12) : 2003 - 2013
  • [9] Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG)
    Heiko Becker
    Stefan Suciu
    Björn Hans Rüter
    Uwe Platzbecker
    Aristoteles Giagounidis
    Dominik Selleslag
    Boris Labar
    Ulrich Germing
    Helmut R. Salih
    Petra Muus
    Karl-Heinz Pflüger
    Anne Hagemeijer
    Hans-Eckart Schaefer
    Valeria Fiaccadori
    Frédéric Baron
    Arnold Ganser
    Carlo Aul
    Theo de Witte
    Pierre W. Wijermans
    Michael Lübbert
    Annals of Hematology, 2015, 94 : 2003 - 2013
  • [10] Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate-or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group
    Luebbert, Michael
    Suciu, Stefan
    Baila, Liliana
    Ruter, Bjorn Hans
    Platzbecker, Uwe
    Giagounidis, Aristoteles
    Selleslag, Dominik
    Labar, Boris
    Germing, Ulrich
    Salih, Helmut R.
    Beeldens, Filip
    Muus, Petra
    Pfluger, Karl-Heinz
    Coens, Corneel
    Hagemeijer, Anne
    Schaefer, Hans Eckart
    Ganser, Arnold
    Aul, Carlo
    de Witte, Theo
    Wijermans, Pierre W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) : 1987 - 1996
12